Angiotensin-receptor blockers in the prevention or treatment of microalbuminuria

Editorial

. 2009 Jul 7;151(1):63-5.

doi: 10.7326/0003-4819-151-1-200907070-00011.

Editorial

Patrick S Parfrey. Ann Intern Med. 2009.

. 2009 Jul 7;151(1):63-5.

doi: 10.7326/0003-4819-151-1-200907070-00011.

No abstract available

Comment on

Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
Bilous R, Chaturvedi N, Sjølie AK, Fuller J, Klein R, Orchard T, Porta M, Parving HH. Bilous R, et al. Ann Intern Med. 2009 Jul 7;151(1):11-20, W3-4. doi: 10.7326/0003-4819-151-1-200907070-00120. Epub 2009 May 18. Ann Intern Med. 2009. PMID: 19451554 Clinical Trial.
Effect of telmisartan on renal outcomes: a randomized trial.
Mann JF, Schmieder RE, Dyal L, McQueen MJ, Schumacher H, Pogue J, Wang X, Probstfield JL, Avezum A, Cardona-Munoz E, Dagenais GR, Diaz R, Fodor G, Maillon JM, Rydén L, Yu CM, Teo KK, Yusuf S; TRANSCEND (Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease) Investigators. Mann JF, et al. Ann Intern Med. 2009 Jul 7;151(1):1-10, W1-2. doi: 10.7326/0003-4819-151-1-200907070-00122. Epub 2009 May 18. Ann Intern Med. 2009. PMID: 19451556 Clinical Trial.

Antihypertensive agents for preventing diabetic kidney disease.
Lv J, Perkovic V, Foote CV, Craig ME, Craig JC, Strippoli GF. Lv J, et al. Cochrane Database Syst Rev. 2012 Dec 12;12(12):CD004136. doi: 10.1002/14651858.CD004136.pub3. Cochrane Database Syst Rev. 2012. PMID: 23235603 Free PMC article. Review.